Abstract
Apelin was identified as natural ligand for APJ, a G protein-coupled receptor. APJ is expressed in spinal cord and dorsal root ganglion. This study was designed to investigate the effects and mechanisms of intrathecally (i.t.) administered apelin-13 on nociceptive response in formalin test and tail-flick test. In formalin test, i.t. injection of apelin-13 (0.3—3 nmol/mouse) had no effect on the nociceptive response in either acute phase (0— 10 min) or interphase (10—20 min), but significantly produced hyperalgesic effect in late phase (20—30 min) at the dose of 3 nmol/mouse. The APJ receptor antagonist apelin-13(F13A) and GABAA receptor antagonist bicuculline methiodide, but not opioid receptor antagonist naloxone, significantly blocked the hyperalgesia caused by apelin-13 in late phase, indicating that i.t. apelin-13- induced hyperalgesia was mediated by APJ and GABAA receptor, rather than opioid receptor. However, in tail-flick test, i.t. injected apelin-13 (1 and 3 nmol/mouse) induced a significant antinociceptive effect, which was significantly antagonized by apelin-13(F13A) and naloxone, suggesting APJ and opioid receptor were involved in the antinociception of spinal apelin-13.
Keywords: Apelin-13, APJ, formalin test, GABA, mice, opioid, tail-flick test.
Protein & Peptide Letters
Title:Intrathecal Apelin-13 Produced Different Actions in Formalin Test and Tail-flick Test in Mice
Volume: 20 Issue: 8
Author(s): Shuang- Yu Lv, Yan Jie Yang, Shangyu Hong, Ning- Bo Wang, Yao- Jun Qin, Wei- Xin Li and Qiang Chen
Affiliation:
Keywords: Apelin-13, APJ, formalin test, GABA, mice, opioid, tail-flick test.
Abstract: Apelin was identified as natural ligand for APJ, a G protein-coupled receptor. APJ is expressed in spinal cord and dorsal root ganglion. This study was designed to investigate the effects and mechanisms of intrathecally (i.t.) administered apelin-13 on nociceptive response in formalin test and tail-flick test. In formalin test, i.t. injection of apelin-13 (0.3—3 nmol/mouse) had no effect on the nociceptive response in either acute phase (0— 10 min) or interphase (10—20 min), but significantly produced hyperalgesic effect in late phase (20—30 min) at the dose of 3 nmol/mouse. The APJ receptor antagonist apelin-13(F13A) and GABAA receptor antagonist bicuculline methiodide, but not opioid receptor antagonist naloxone, significantly blocked the hyperalgesia caused by apelin-13 in late phase, indicating that i.t. apelin-13- induced hyperalgesia was mediated by APJ and GABAA receptor, rather than opioid receptor. However, in tail-flick test, i.t. injected apelin-13 (1 and 3 nmol/mouse) induced a significant antinociceptive effect, which was significantly antagonized by apelin-13(F13A) and naloxone, suggesting APJ and opioid receptor were involved in the antinociception of spinal apelin-13.
Export Options
About this article
Cite this article as:
Lv Yu Shuang-, Yang Jie Yan, Hong Shangyu, Wang Bo Ning-, Qin Jun Yao-, Li Xin Wei- and Chen Qiang, Intrathecal Apelin-13 Produced Different Actions in Formalin Test and Tail-flick Test in Mice, Protein & Peptide Letters 2013; 20 (8) . https://dx.doi.org/10.2174/0929866511320080010
DOI https://dx.doi.org/10.2174/0929866511320080010 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Intradialytic Hypertension: An Under-recognized Cardiovascular Risk Factor. What is the Evidence?
Current Hypertension Reviews Ribonucleases, Nucleases and Antiangiogenins in Antiproliferative Activities
Current Signal Transduction Therapy Treatment of Hypertensive Complications in Pregnancy
Current Pharmaceutical Design Engineered Inorganic/Organic-Core/Shell Magnetic Fe<sub>x</sub>O<sub>y</sub> Nanoparticles with Oleic Acid and/or Oleylamine As Capping Agents
Current Pharmaceutical Design Radiolabeled Probes Targeting Tyrosine-Kinase Receptors For Personalized Medicine
Current Pharmaceutical Design Thrombolytic Treatment of Cardiac Myxoma-Induced Ischemic Stroke: A Review
Current Drug Safety Phosphodiesterase Inhibition as a Therapeutic Target for Brain Ischemia
CNS & Neurological Disorders - Drug Targets The Application of Angiotensin Converting Enzyme Inhibitors in Heart Surgery
Letters in Drug Design & Discovery Endothelin Receptors in Gastrointestinal Smooth Muscle
Current Protein & Peptide Science Obstructive Sleep Apnoea Syndrome and Diabetes. Fortuitous Association or Interaction?
Current Diabetes Reviews Efficacy and Safety of H1-Antihistamines: An Update
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Phospholipase A2 Myotoxins from Bothrops Snake Venoms: Structure- Function Relationship
Current Organic Chemistry Preconception Care for the Type 2 Diabetic Mother: A Review on Current Care Guidelines
Current Women`s Health Reviews Assessing and Treating Cognitive Impairment in Schizophrenia: Current and Future
Current Pharmaceutical Design Biochemical Markers in the Prediction of Contrast-induced Acute Kidney Injury
Current Medicinal Chemistry Chymase as an Important Target for Preventing Complications of Metabolic Syndrome
Current Medicinal Chemistry Tremor and Rigidity in Patients with Parkinson’s Disease: Emphasis on Epidemiology, Pathophysiology and Contributing Factors
CNS & Neurological Disorders - Drug Targets The Role of Growth Factors in the Prevention and Treatment of Chemotherapy-Induced Peripheral Neurotoxicity
Current Drug Safety Clinical Pharmacology of Frequently Used Intravenous Drugs During Bariatric Surgery in Adolescents
Current Pharmaceutical Design Therapeutic Properties of Mushrooms in Managing Adverse Effects in the Metabolic Syndrome
Current Topics in Medicinal Chemistry